Full Press Release Details
Material Change Report
Aurinia Pharmaceuticals Inc. (the "Company") #1203-4464 Markham Street Victoria, BC A1 V8Z 7X8
A news release was issued and disseminated by the Company through Business Wire on June 15, 2016.
The Company announced, subject to regulatory approval, a US$7,080,000 private placement (the "Offering").
On June 15, 2016, the Company announced the Offering. The Company intends to use the net proceeds from the Offering for general corporate purposes, including financing research and development, clinical expenses, and corporate costs.
Under the terms of the Offering, the Company will issue 3,000,000 units (the "Units") at a subscription price per Unit of US$2.36, each Unit consisting of one common share ("Common Share") and 0.35 of one common share purchase warrant (each full warrant, a "Warrant"), with each Warrant exercisable for a period of 24 months from the date of closing of the Offering at an exercise price of US$2.77.
Canaccord Genuity Inc. acted as placement agent for the Offering.
No significant facts remain confidential in, and no information has been omitted from, this report.
For further information, please contact:
Mr. Michael R. Martin, Chief Operating Officer